ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Referral Pattern Change Needed For Quality Care, AACR/ASCO Told

May 16, 1975

Drug Development Effort Criticized

April 18, 1975

NCCS Networker Volume 2 Issue 4, Fall 1988

September 13, 1988

DCT Board Approves Three New BRMP RFAs For Immunologic Research, $1.5 Million A Year

February 27, 1987

Groups Urge Congress To Enact NIH Budget Increase; Encourage Individual Letters

November 3, 1995

Chabner On Taxol, NSABP: “Makes You Lose Confidence In The Political Process”

May 12, 1995